Key points are not available for this paper at this time.
On the basis of personal results and reports of others, the authors found that in well-differentiated squamous-cell laryngeal carcinoma the “standard” dose of 6,000 rads in 30 treatments over six weeks (NSD of 1,770 rets) is inadequate when megavoltage is used. For T1N0 and T2N0 lesions they recommend a tumor dose biologically equivalent to at least 6,000 rads in five weeks with 5 treatments per week (1,900 rets): this is below the tolerance dose of the larynx. For T3N0 lesions they suggest a dose biologically equivalent to at least 7,200 rads in six weeks with 5 treatments per week (2,100 rets).
Aristizabal et al. (1972) studied this question.